pegozafermin
Behind-the-Scenes Details of 89bio’s $2.4B Deal with Roche
Roche; 89bio; pegozafermin; MASH; liver disease; contingent value rights; biotech acquisition; pharmaceuticals; deal structure; milestone payments
Roche Acquires 89bio with $2.4 Billion Buyout to Enter FGF21 MASH Therapeutics Space
Roche; 89bio; acquisition; FGF21; pegozafermin; MASH; metabolic dysfunction-associated steatohepatitis; liver disease; biotech; contingent value rights; cardiometabolic diseases